SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending as its highly active community demonstrates relentless "proof of work" by building a permissionless brand with tangible products like Kendu Spice, soon launching on Amazon. The enthusiastic holders highlight the project's strong real-world presence and continuous development across multiple chains, fueling conviction in its ambitious long-term vision to become a household name.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp (OMER) is trending following the recent FDA approval of YARTEMLEA, its first-in-class treatment for transplant-associated thrombotic microangiopathy, addressing a severe condition with no current alternatives. The community is actively discussing the significant revenue potential from this market monopoly and the company's strengthened financial position due to a major partnership and debt reduction. Investors are keenly awaiting the upcoming conference call for further commercialization details and potential additional catalysts.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as traders navigate expectations of a year-end rally and anticipated Federal Reserve rate cuts, driving significant bullish speculation in the tech-heavy Nasdaq. The recent 2-for-1 stock split has sparked community debate, with many seeing it as a potential catalyst for renewed buying interest, while others express caution regarding amplified market volatility and the long-term sustainability of the AI-driven rally. Sentiment remains divided, balancing aggressive upside bets against concerns over leveraged exposure in a dynamic market.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is trending due to extreme price volatility and massive trading volume, fueled by speculation around its low float and high borrow rate. The community is actively debating a potential short squeeze, comparing its wild swings to past parabolic runners, while others warn of a pump and dump scenario, highlighting its nature as a high-risk SPAC play.

Paysafe Ltd. provides online payment solutions. The firm operates through the following segments: Merchant Solutions and Digital Wallet. The Merchant Solutions business segment focuses on card not present and card present solutions for small to medium size business merchants. The Digital Wallet business segment provides wallet based online payment solutions through its Skrill, eCash solutions and NETELLER brands. The company was founded in 1996 and is headquartered in London, the United Kingdom.

Paysafe Limited

Paysafe Ltd

Paysafe Ltd. is trending due to recent weak earnings results and a lowered outlook, fueling a polarized debate among investors. Bears frequently label the company a "SPAC scam" citing continuous underperformance, growing debt, and perceived management incompetence, while a bullish faction contends it is "grossly undervalued" given its payment volumes and strategic initiatives, anticipating a potential re-rate from buybacks or a private takeover. This fintech firm's struggles are contrasted against broader market rallies, amplifying discussions around its long-term viability and ability to deliver consistent growth.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is making significant waves in the cybersecurity landscape, driven by an expanded multi-year partnership with Google Cloud focused on AI security and recent strategic acquisitions. The community is buzzing with discussions on its long-term growth potential in a booming sector, even as some traders evaluate recent price movements as a compelling buy-the-dip opportunity for this platform leader.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is experiencing a surge in trading activity, fueled by broader AI sector momentum and heightened interest in its Gemini-II APU. The community is actively discussing the chip's potential for power-efficient edge AI, especially for defense and drone applications, citing recent government contracts and anticipated multi-modal Large Language Model benchmarks. This positions GSI as a potential disruptor in the expanding market for specialized AI inference hardware.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is at the center of investor discussion as its Anaphylm sublingual film nears a pivotal regulatory decision in January, with many anticipating approval as a convenient, needle-free option for anaphylaxis. The community is actively debating a potential pre-approval rally and short squeeze, highlighting Anaphylm's distinct portability advantage over traditional devices and competitor products. Ongoing FDA workshops on epinephrine access further emphasize the market's evolving landscape and Aquestive's strategic positioning.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1996 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Cheniere Energy (LNG) is a focal point as the community discusses its oversold condition and long-term value, driven by escalating global demand for liquefied natural gas. The company is poised to benefit from Europe's hastened pivot away from Russian gas and the immense power requirements of AI data centers, further bolstered by its expanding U.S. export capacity.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending due to significant technical advancements like quantum-safe state proofs and new ecosystem integrations, including regulated payment infrastructure and the Algorand decentralization tracker. This has polarized the community, with many accumulating for its long-term utility and strong fundamentals, while others express frustration over past price performance and concerns regarding the Algorand Foundation's token supply strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading on Wednesday. Stock traders bought 4,063 put options on the stock. This is an increase of...

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company

Wells Fargo & Company increased their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an "overweight" rating in a research report on Thursday...

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders acquired 4,063 put options on the stock. This represents an...

Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 10,830 shares of Xenon Pharmaceuticals stock in a transaction dated Monday, December 8th. The stock was sold at an...

Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 14,375 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 14,375 shares of the business's stock in a transaction dated Friday, December 5th. The shares were sold at an average...

Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE

Marshall Wace LLP increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 34.6% during the second quarter, according to the company in its most recent 13F filing with the...

New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE

New York State Common Retirement Fund raised its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 16.9% in the second quarter, according to its most recent 13F filing...

Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

Rhumbline Advisers grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 378,175.9% in the second quarter, according to its most recent disclosure with the Securities and...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned a consensus rating of "Buy" from the fourteen analysts that are currently covering the firm, MarketBeat.com reports. One...

Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week High - Here's What Happened

Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 1-Year High - Here's What Happened...

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.19	--	--	N/A
Q3 '25	-$1.15	-$1.15	0.21%	BEAT
Q2 '25	-$0.99	-$1.07	-8.36%	MISSED
Q1 '25	-$0.91	-$0.83	8.30%	BEAT
Q4 '24	-$0.86	-$0.84	2.39%	BEAT

XENE
Xenon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest XENE News

XENEXenon Pharmaceuticals Inc